Hydroxy Chloroquine Prophylaxis Experience in Doctor Community with COVID-19 in West Bengal
et al., Journal of College of Medical Sciences-Nepal, doi:10.3126/jcmsn.v20i2.43302, Jun 2024
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,200+ studies for
200+ treatments. c19early.org
|
Retrospective 117 COVID-19 positive doctors in India showing lower mortality and severity with HCQ prophylaxis, without statistical significance in unadjusted results without group details. Results do not include the risk of positive cases.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details.
|
risk of death, 91.5% lower, RR 0.08, p = 0.09, treatment 0 of 41 (0.0%), control 7 of 76 (9.2%), NNT 11, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of moderate/severe case, 27.5% lower, RR 0.73, p = 0.39, treatment 9 of 41 (22.0%), control 23 of 76 (30.3%), NNT 12.
|
|
risk of hospitalization, 16.3% lower, RR 0.84, p = 0.55, treatment 14 of 41 (34.1%), control 31 of 76 (40.8%), NNT 15.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Dey et al., 30 Jun 2024, retrospective, India, peer-reviewed, mean age 41.1, 6 authors, study period 26 August, 2020 - 25 November, 2020.
Contact: tsabui@gmail.com.
Hydroxy Chloroquine Prophylaxis Experience in Doctor Community with COVID-19 in West Bengal
Journal of College of Medical Sciences-Nepal, doi:10.3126/jcmsn.v20i2.43302
Background The Indian Council of Medical Research (ICMR)National task Force for COVID-19 reviewed the data on in-vitro testing of Hydroxy Chloroquine (HCQ)for antiviral efficacy against SARS-CoV-2, safety profile and recommended it's use for prophylaxis among health care workers (HCWs). The efficacy of HCQ against Covid -19 has been the subject of contradictory results. Given the need for insights into the clinical outcomes and side effects among doctors on prophylaxis with hydroxychloroquine, we conducted a retrospective analysis of doctors treated at home or hospital with COVID-19 infection.
Methods The data was collected by direct interview, electronic data transfer from COVID-19 positive doctors using real-time reverse transcription-polymerase chain reaction (RT-PCR) test from two medical colleges, friends and relatives of doctors who voluntarily provided their illness information during the period of August, 26 to Nov 25, 2020.
Results A total of 117 doctors participated in study. Out of 117 covid positive doctors, 76 received no HCQ prophylaxis and 41 received prophylaxis till the onset of the symptom. Out of 117 positive doctors, 32(27%) developed moderate to severe (MS) illness. Nine doctors (22%) developed MS in HCQ group and none of them died. Out of no HCQ group 23(30%) developed MS illness and 7(9%) died. There was no statistically significant relation between use of HCQ and outcomes of disease. The most common (22%) side effect of HCQ prophylaxis was related to gastrointestinal system.
Conclusions Hydroxy Chloroquine has a disease modifying effect on COVID-19 disease although it is not robust.
Conflict of interest: None
References
Abella, Jolkovsky, Biney, Efficacy and safety of hydroxychloroquinevs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial, JAMA Intern Med, doi:10.1001/jamainternmed.2020.6319
Devaux, Rolain, Colson, Raoult, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105938
Fantini, Scala, Chahinian, Yahi, Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection, IntJAntimicrob Agents, doi:10.1016/j.ijantimicag.2020.105960
Gandhi, Lynch, Del Rio, Mild or Moderate COVID-19, N Engl J Med
Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrlert et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, doi:10.1038/s41421-020-0156-0
Lofgren, Nicol, Bangdiwala, Pastick, Okafor et al., Safety of hydroxychloroquine among outpatient clinical trial participantsfor COVID-19, Open Forum InfectDis
Mikami, Miyashita, Yamada, Risk Factors for Mortality in Patients with COVID-19 in New York City, J GEN INTERN MED, doi:10.1007/s11606-020-05983-z
Rajasingham, Bangdiwala, Nicol, Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial, Nephrol Dial Transplant, doi:10.1093/cid/ciaa1571
Raphael, Stricker, Fesler, Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India:A Meta-Analysis, Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.001
Reedac, Jessicaj, Long, Dena, Ariel et al., Drug treatments for COVID-19: living systematic review and network meta-analysis, BMJ, doi:10.1136/bmj.m2980
Rentsch, Devito, Mackenna, Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform, Lancet Rheumatol, doi:10.1016/S2665-9913(20)30378-7
Schrezenmeier, Dörner, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol, doi:10.1038/s41584-020-0372-x
DOI record:
{
"DOI": "10.3126/jcmsn.v20i2.43302",
"ISSN": [
"2091-0673",
"2091-0657"
],
"URL": "http://dx.doi.org/10.3126/jcmsn.v20i2.43302",
"abstract": "<jats:p>Background The Indian Council of Medical Research (ICMR)National task Force for COVID-19 reviewed the data on in-vitro testing of Hydroxy Chloroquine (HCQ)for antiviral efficacy against SARS-CoV-2, safety profile and recommended it’s use for prophylaxis among health care workers (HCWs). The efficacy of HCQ against Covid -19 has been the subject of contradictory results. Given the need for insights into the clinical outcomes and side effects among doctors on prophylaxis with hydroxychloroquine, we conducted a retrospective analysis of doctors treated at home or hospital with COVID-19 infection.MethodsThe data was collected by direct interview, electronic data transfer from COVID-19 positive doctors using real-time reverse transcription-polymerase chain reaction (RT-PCR) test from two medical colleges, friends and relatives of doctors who voluntarily provided their illness information during the period of August, 26 to Nov 25, 2020.ResultsA total of 117 doctors participated in study. Out of 117 covid positive doctors, 76 received no HCQ prophylaxis and 41 received prophylaxis till the onset of the symptom. Out of 117 positive doctors, 32(27%) developed moderate to severe (MS) illness. Nine doctors (22%) developed MS in HCQ group and none of them died. Out of no HCQ group 23(30%) developed MS illness and 7(9%) died. There was no statistically significant relation between use of HCQ and outcomes of disease. The most common (22%) side effect of HCQ prophylaxis was related to gastrointestinal system. Conclusions Hydroxy Chloroquine has a disease modifying effect on COVID-19 disease although it is not robust.</jats:p>",
"author": [
{
"ORCID": "http://orcid.org/0000-0003-2356-7627",
"affiliation": [],
"authenticated-orcid": false,
"family": "Dey",
"given": "Pranab Kumar",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0003-0009-9074",
"affiliation": [],
"authenticated-orcid": false,
"family": "Sabui",
"given": "Tapas Kumar",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0003-2856-4839",
"affiliation": [],
"authenticated-orcid": false,
"family": "Chowdhury",
"given": "Sreetama",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0003-3893-7811",
"affiliation": [],
"authenticated-orcid": false,
"family": "Banerjee",
"given": "Joyashree",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-0349-2579",
"affiliation": [],
"authenticated-orcid": false,
"family": "Sabui",
"given": "Abhisek",
"sequence": "additional"
},
{
"ORCID": "http://orcid.org/0000-0002-0105-0937",
"affiliation": [],
"authenticated-orcid": false,
"family": "Choudhuri",
"given": "Jashodhara",
"sequence": "additional"
}
],
"container-title": "Journal of College of Medical Sciences-Nepal",
"container-title-short": "J Coll Med Sci-Nepal",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2024,
7,
1
]
],
"date-time": "2024-07-01T12:18:48Z",
"timestamp": 1719836328000
},
"deposited": {
"date-parts": [
[
2024,
7,
1
]
],
"date-time": "2024-07-01T12:19:20Z",
"timestamp": 1719836360000
},
"indexed": {
"date-parts": [
[
2024,
7,
2
]
],
"date-time": "2024-07-02T00:17:13Z",
"timestamp": 1719879433937
},
"is-referenced-by-count": 0,
"issue": "2",
"issued": {
"date-parts": [
[
2024,
6,
30
]
]
},
"journal-issue": {
"issue": "2",
"published-online": {
"date-parts": [
[
2024,
7,
1
]
]
}
},
"license": [
{
"URL": "https://creativecommons.org/licenses/by-nc-nd/4.0",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2024,
6,
30
]
],
"date-time": "2024-06-30T00:00:00Z",
"timestamp": 1719705600000
}
}
],
"link": [
{
"URL": "https://www.nepjol.info/index.php/JCMSN/article/download/43302/51429",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://www.nepjol.info/index.php/JCMSN/article/download/43302/51429",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "1670",
"original-title": [],
"page": "147-152",
"prefix": "10.3126",
"published": {
"date-parts": [
[
2024,
6,
30
]
]
},
"published-online": {
"date-parts": [
[
2024,
6,
30
]
]
},
"publisher": "Nepal Journals Online (JOL)",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.nepjol.info/index.php/JCMSN/article/view/43302"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Hydroxy Chloroquine Prophylaxis Experience in Doctor Community with COVID-19 in West Bengal",
"type": "journal-article",
"volume": "20"
}